Breckenridge duloxetine refund program

Breckenridge Pharmaceutical Inc. has reached a class action settlement resolving claims that its generic duloxetine (Cymbalta) contained a cancer-causing impurity.

In 2024, Breckenridge recalled generic duloxetine products. Duloxetine is an antidepressant that is also used to treat anxiety, diabetic nerve pain, fibromyalgia and chronic pain.

While Breckenridge denies any wrongdoing, it agreed to both a class action settlement and a duloxetine recall refund program to resolve these allegations.

Under the generic Cymbalta settlement, eligible consumers may have two separate ways to receive a refund:

• a Class Action Settlement covering certain past purchases, and
  
• a Future Refund Program for products subject to a recall initiated after May 22, 2025.
  

Class Action Settlement Refund Program

Under the terms of the class action settlement, eligible consumers who paid for a prescription of Breckenridge duloxetine before May 22, 2025, may be entitled to a cash payment, depending on the product purchased and the documentation provided.

• Class members can receive a single $5 payment with proof of purchase, such as pharmacy or insurance records.
  
• Class members who purchased duloxetine from recalled lot numbers may receive a single $7.50 payment with proof of purchase or documentation showing the affected lot number.
  
• Instead of these flat payments, some consumers may qualify for up to $10 per prescription if they were unable to use their medication due to the recall. To qualify, claimants must provide proof of purchase and either return unused recalled medication or submit a sworn certification.
  

By participating in the class action settlement, class members release certain economic claims related to duloxetine purchases made during the settlement period.

Claims under the Class Action Settlement Refund must be submitted by Dec. 27, 2025.

2. Future Refund Program

In addition to the class action settlement, Breckenridge has established a separate Future Refund Program.

The Future Refund Program applies only to Breckenridge duloxetine recalled after May 22, 2025.

Under this program, eligible consumers may receive a refund of their actual out-of-pocket costs for unused recalled duloxetine, provided they return the medication and submit a valid claim.

Consumers may be eligible for a Future Refund Program refund even if they also submitted a claim under the class action settlement, as long as the recall occurred after May 22, 2025.

Claims under the Future Refund Program must be submitted by Jan. 1, 2028.

Who’s Eligible

Class Action Settlement: All natural persons in the United States who purchased Breckenridge duloxetine, for personal or household use, from Aug. 4, 2020, until May 22, 2025.

Future Refund Program: All natural persons in the United States who purchased qualifying recalled Breckenridge duloxetine after May 22, 2025.

Potential Award

Up to $10 per prescription or a full refund of your out-of-pocket costs.

Proof of Purchase

An original pharmacy receipt, copy of a pharmacy receipt, other pharmacy records, insurance records, documentation identifying recalled lot numbers, and documentation showing the pharmacy name and address.

Additional documentation and product return requirements apply for the Future Refund Program.

Claim Form

NOTE: If you do not qualify for this settlement do NOT file a claim.

Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.

Claim Form Deadline

Class Action Settlement: 12/27/2025

Future Refund Program: 01/01/2028

Case Name

Boyer v. Breckenridge Pharmaceutical Inc., Case No. 2:24-cv-06514-JKS-JBC, in the U.S. District Court for the District of New Jersey

Final Hearing

Class Action Settlement: Sept. 23, 2025

Future Refund Program: N/A

Settlement Website

BoyerSettlement.com

BreckenridgeFutureRefundProgram.com

Claims Administrator

Boyer v. Breckenridge Pharmaceuticals Claims Administrator
P.O. Box 301132
Los Angeles, CA 90030-1132
[email protected]
833-688-8988

Class Counsel

Aaron K. Block
Max Marks
THE BLOCK FIRM LLC

Defense Counsel

Melissa O’Donnell
Kyle A. Dolinsky
TROUTMAN PEPPER HAMILTON SANDERS LLP